FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998073418> ?p ?o ?g. }

• W1998073418 endingPage "297" @default.
• W1998073418 startingPage "297" @default.
• W1998073418 abstract "A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors Helmy M SiragyProfessor of Medicine and Endocrinology, Department of Medicine, Director, Hypertension Center, University of Virginia Health System, Charlottesville, VA, USAAbstract: The safety of angiotensin II receptor blockers (ARBs) for the treatment of hypertension and cardiovascular and renal diseases has been well documented in numerous randomized clinical trials involving thousands of patients. However, recent concerns have surfaced about possible links between ARBs and increased risks of myocardial infarction and cancer. Less is known about the safety of the direct renin inhibitor aliskiren, which was approved as an antihypertensive in 2007. This article provides a detailed review of the safety of ARBs and aliskiren, with an emphasis on the risks of cancer and myocardial infarction associated with ARBs. Safety data were identified by searching PubMed and Food and Drug Administration (FDA) Web sites through April 2011. ARBs are generally well tolerated, with no known class-specific adverse events. The possibility of an increased risk of myocardial infarction associated with ARBs was suggested predominantly because the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial reported a statistically significant increase in the incidence of myocardial infarction with valsartan compared with amlodipine. However, no large-scale, randomized clinical trials published after the VALUE study have shown a statistically significant increase in the incidence of myocardial infarction associated with ARBs compared with placebo or non-ARBs. Meta-analyses examining the risk of cancer associated with ARBs have produced conflicting results, most likely due to the inherent limitations of analyzing heterogeneous data and a lack of published cancer data. An ongoing safety investigation by the FDA has not concluded that ARBs increase the risk of cancer. Pooled safety results from clinical trials indicate that aliskiren is well tolerated, with a safety profile similar to that of placebo. ARBs and aliskiren are well tolerated in patients with hypertension and certain cardiovascular and renal conditions; their benefits outweigh possible safety concerns.Keywords: angiotensin II receptor blocker, renin-angiotensin system, aliskiren, safety, myocardial infarction, cancer" @default.
• W1998073418 created "2016-06-24" @default.
• W1998073418 creator A5045403863 @default.
• W1998073418 date "2011-05-01" @default.
• W1998073418 modified "2023-10-16" @default.
• W1998073418 title "A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors" @default.
• W1998073418 cites W1511980763 @default.
• W1998073418 cites W1514653714 @default.
• W1998073418 cites W1532542861 @default.
• W1998073418 cites W1541017615 @default.
• W1998073418 cites W157136288 @default.
• W1998073418 cites W161188740 @default.
• W1998073418 cites W1967418523 @default.
• W1998073418 cites W1970465782 @default.
• W1998073418 cites W1974816905 @default.
• W1998073418 cites W1978998472 @default.
• W1998073418 cites W1979030376 @default.
• W1998073418 cites W1980977337 @default.
• W1998073418 cites W1981042423 @default.
• W1998073418 cites W1992298826 @default.
• W1998073418 cites W1994079702 @default.
• W1998073418 cites W1995868309 @default.
• W1998073418 cites W2001722069 @default.
• W1998073418 cites W2014096159 @default.
• W1998073418 cites W2021011733 @default.
• W1998073418 cites W2022431693 @default.
• W1998073418 cites W2024159102 @default.
• W1998073418 cites W2031278591 @default.
• W1998073418 cites W2044056481 @default.
• W1998073418 cites W2045615482 @default.
• W1998073418 cites W2052710347 @default.
• W1998073418 cites W2053645304 @default.
• W1998073418 cites W2056814966 @default.
• W1998073418 cites W2056893352 @default.
• W1998073418 cites W2056976690 @default.
• W1998073418 cites W2061559923 @default.
• W1998073418 cites W2067722551 @default.
• W1998073418 cites W2068519950 @default.
• W1998073418 cites W2084526331 @default.
• W1998073418 cites W2085686527 @default.
• W1998073418 cites W2089072737 @default.
• W1998073418 cites W2091328577 @default.
• W1998073418 cites W2093774213 @default.
• W1998073418 cites W2097245721 @default.
• W1998073418 cites W2098780362 @default.
• W1998073418 cites W2100082183 @default.
• W1998073418 cites W2104840297 @default.
• W1998073418 cites W2105473163 @default.
• W1998073418 cites W2106285152 @default.
• W1998073418 cites W2109051856 @default.
• W1998073418 cites W2111421663 @default.
• W1998073418 cites W2112237782 @default.
• W1998073418 cites W2112906259 @default.
• W1998073418 cites W2118795360 @default.
• W1998073418 cites W2126045082 @default.
• W1998073418 cites W2127254785 @default.
• W1998073418 cites W2128957326 @default.
• W1998073418 cites W2133217116 @default.
• W1998073418 cites W2135038122 @default.
• W1998073418 cites W2140319788 @default.
• W1998073418 cites W2143954917 @default.
• W1998073418 cites W2143966259 @default.
• W1998073418 cites W2145632481 @default.
• W1998073418 cites W2146798390 @default.
• W1998073418 cites W2152798629 @default.
• W1998073418 cites W2160643831 @default.
• W1998073418 cites W2160654062 @default.
• W1998073418 cites W2163395116 @default.
• W1998073418 cites W2166155176 @default.
• W1998073418 cites W2168907840 @default.
• W1998073418 cites W2171829664 @default.
• W1998073418 cites W2172032309 @default.
• W1998073418 cites W75251984 @default.
• W1998073418 cites W2084093508 @default.
• W1998073418 doi "https://doi.org/10.2147/vhrm.s15541" @default.
• W1998073418 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3104607" @default.
• W1998073418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21633727" @default.
• W1998073418 hasPublicationYear "2011" @default.
• W1998073418 type Work @default.
• W1998073418 sameAs 1998073418 @default.
• W1998073418 citedByCount "21" @default.
• W1998073418 countsByYear W19980734182012 @default.
• W1998073418 countsByYear W19980734182013 @default.
• W1998073418 countsByYear W19980734182014 @default.
• W1998073418 countsByYear W19980734182015 @default.
• W1998073418 countsByYear W19980734182016 @default.
• W1998073418 countsByYear W19980734182017 @default.
• W1998073418 countsByYear W19980734182021 @default.
• W1998073418 countsByYear W19980734182023 @default.
• W1998073418 crossrefType "journal-article" @default.
• W1998073418 hasAuthorship W1998073418A5045403863 @default.
• W1998073418 hasBestOaLocation W19980734181 @default.
• W1998073418 hasConcept C126322002 @default.
• W1998073418 hasConcept C168563851 @default.
• W1998073418 hasConcept C177713679 @default.
• W1998073418 hasConcept C197934379 @default.
• W1998073418 hasConcept C198710026 @default.
• W1998073418 hasConcept C2777387769 @default.

• next